Craig Wheeler Appointed to Apellis Board of Directors
Apellis Pharmaceuticals, Inc. has made a significant move by appointing Craig Wheeler, the founder and chief executive officer of Headwaters Biotech Advisors, to its Board of Directors. This addition marks an important step in the company's journey in the biopharmaceutical industry, as it seeks to improve its leadership depth and strategic oversight.
Strengthening Leadership with Proven Experience
As an executive with over three decades of experience, Mr. Wheeler is well-versed in guiding biopharmaceutical companies from inception to robust commercial success. His tenure in the industry has set a strong precedent for future growth, which is vital for Apellis as it works to deliver innovative therapies to patients in need.
“We are thrilled to have Craig joining our Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder of Apellis. “His depth of knowledge in the industry, especially in growing companies with diverse biopharmaceutical pipelines, will be an invaluable resource for our team as we pave the way for breakthrough treatments.”
Previous Leadership Roles Enhance His Suitability
Before joining Apellis, Mr. Wheeler was at the helm of Momenta Pharmaceuticals for a remarkable 14 years, guiding the company through its early days all the way to significant product launches and its acquisition by Johnson & Johnson. Additionally, his leadership history includes serving as president of Chiron Biopharmaceuticals, managing a substantial workforce dedicated to innovation in healthcare.
Further diversifying his experience, Craig also holds positions on the Boards of several other respected organizations, including Amicus Therapeutics and the California Healthcare Institute. His comprehensive understanding of both operational and strategic aspects of biopharmaceutical firms will greatly complement Apellis' objectives.
A Vision Aligned with Apellis' Mission
Wheeler expressed his enthusiasm about joining Apellis, stating, “I have long admired Apellis’s commitment to advancing innovative therapies for patients with significant unmet needs. My previous experience with an immunology-focused company has shown me that Apellis’s approach is among the best in the industry.” He is eager to collaborate with the talented leadership team at Apellis as they strive toward ambitious goals.
Educational Background Reinforces His Capabilities
Craig Wheeler’s academic background further enhances his qualifications. He earned a Master of Business Administration in Finance and Marketing from the Wharton School at the University of Pennsylvania and holds both a Bachelor of Science and a Master of Science in Chemical Engineering from Cornell University. This solid foundation in both business and engineering primes him for impactful contributions to Apellis.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is not just a biopharmaceutical entity; it's a pioneer committed to combining groundbreaking scientific research with compassion to develop transformative therapies for the most challenging diseases. They have recently introduced the first new class of complement medicine in a considerable timeframe and now have two approved medications that target C3, which is crucial for treating conditions such as geographic atrophy—a leading cause of blindness. Apellis believes that the potential for targeting C3 extends across a variety of serious diseases, positioning itself uniquely in the healthcare landscape.
For deeper insights into their work and the innovative avenues they're pursuing, you can visit Apellis Pharmaceuticals or connect with them on Twitter and LinkedIn.
Frequently Asked Questions
1. Who is Craig Wheeler?
Craig Wheeler is the founder and CEO of Headwaters Biotech Advisors and has over 30 years of experience in the biopharmaceutical industry.
2. What role will Craig Wheeler play at Apellis?
Craig will join the Board of Directors, contributing his extensive expertise in growing biopharmaceutical companies.
3. What is the primary focus of Apellis Pharmaceuticals?
Apellis focuses on developing innovative therapies aimed at treating serious diseases, particularly through complement medicine.
4. What significant achievements has Craig Wheeler accomplished?
He led Momenta Pharmaceuticals through crucial product launches and its acquisition by Johnson & Johnson during his tenure as CEO.
5. How does Apellis view the future of its therapies?
Apellis is optimistic about unlocking new potential in targeting C3 across various serious diseases, with recently approved treatments already making a difference.
